Advanced hepatocellular carcinoma treated effectively with irinotecan via hepatic arterial infusion followed by proton beam therapy

Journal of Infection and Chemotherapy

Volumn 15, Issue 5, 2009, Pages 316-321

  Ohtsubo, Koushiro ^a   Watanabe, Hiroyuki ^a   Tsuchiyama, Tomoya ^a   Mouri, Hisatsugu ^a   Yamaguchi, Yasushi ^a   Motoo, Yoshiharu ^a   Okai, Takashi ^a   Sanada, Junichiro ^a   Matsui, Osamu ^a   Kitamura, Tokuji ^b   Fujiki, Ryusuke ^c   Tokuuye, Koichi ^d   Sawabu, Norio ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b Kitamura Clinic   (Japan)

^c Fujiki Hospital   (Japan)

^d UNIVERSITY OF TSUKUBA HOSPITAL   (Japan)

Author keywords

Docetaxel; Hepatic arterial infusion; Hepatocellular carcinoma; Hyperthermia; Irinotecan; Proton beam therapy

Indexed keywords

ALPHA FETOPROTEIN; ALPHA INTERFERON; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FOLINATE CALCIUM; IRINOTECAN; MITOMYCIN C;

ADULT; ADVANCED CANCER; ARTICLE; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER SURVIVAL; CASE REPORT; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; DISTANT METASTASIS; DRUG DOSE REDUCTION; DRUG EFFICACY; ECHOGRAPHY; HEPATIC ARTERY; HEPATITIS C; HUMAN; HYPERTHERMIC THERAPY; LABORATORY TEST; LIVER ANGIOGRAPHY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER RESECTION; LOW DRUG DOSE; MALE; MICROWAVE THERAPY; NEUTROPENIA; PORTAL VEIN THROMBOSIS; PROTON THERAPY; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 70350508590     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-009-0702-z     Document Type: Article

References (22)

1. J.M. Llovet J. Bustamante A. Castells R. Vilana M. d. C. Ayuso M. Sala, et al. 1999 Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials Hepatology 29 62 67 10.1002/hep.510290145 1:STN:280:DyaK1M%2FotFKrsw%3D%3D 9862851 (Pubitemid 29023987)
2. T. Fujii K. Takayasu Y. Muramatsu N. Moriyama F. Wakao T. Kosuge, et al. 1993 Hepatocellular carcinoma with portal tumor thrombus: analysis of factors determining prognosis Jpn J Clin Oncol 23 105 109 1:STN:280:DyaK3s3psV2ktQ%3D%3D 8390584
3. Y.Z. Patt M.M. Hassan R.D. Lozano T.D. Brown J.N. Vauthey S.A. Curley, et al. 2003 Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon alfa-2b for treatment of hepatocellular carcinoma J Clin Oncol 21 421 427 10.1200/JCO.2003.10.103 1:CAS:528:DC%2BD2cXpsVGrt7g%3D 12560429 (Pubitemid 46606469)
4. E. Ando M. Tanaka F. Yamashita R. Kuromatsu S. Yutani K. Fukumori, et al. 2002 Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases Cancer 95 588 595 10.1002/cncr.10694 12209752 (Pubitemid 34810185)
5. S. Obi H. Yoshida R. Toune T. Unuma M. Kanda S. Sato, et al. 2006 Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion Cancer 106 1990 1997 10.1002/cncr.21832 1:CAS:528:DC%2BD28XkvFGhs7s%3D 16565970 (Pubitemid 43673215)
6. H. Ota H. Nagano M. Sakon H. Eguchi M. Kondo T. Yamamoto, et al. 2005 Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type I interferon receptor expression Br J Cancer 93 557 564 10.1038/sj.bjc.6602742 1:CAS:528:DC%2BD2MXpsFalurg%3D 16106266 (Pubitemid 43079999)
7. J.M. Collins 1984 Pharmacologic rationale for regional drug delivery J Clin Oncol 2 498 504 1:STN:280:DyaL2c3hsFahug%3D%3D 6547166
8. J.M. Llovet 2005 Updated treatment approach to hepatocellular carcinoma J Gastroenterol 40 225 235 10.1007/s00535-005-1566-3 15830281 (Pubitemid 40613379)
9. M. Minagawa M. Makuuchi 2006 Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus World J Gastroenterol 12 7561 7567 1:CAS:528:DC%2BD2sXhtleqtrY%3D 17171782
10. E.E. Tzoracoleftherakis J.D. Spiliotis T. Kyriakopoulou S.K. Kakkos 1999 Intra-arterial versus systemic chemotherapy for non-operable hepatocellular carcinoma Hepatogastroenterology 46 1122 1125 1:STN:280:DyaK1M3pvVyitA%3D%3D 10370678
11. E.M. O'Reilly K.E. Stuart P.M. Sanz-Altamira G.K. Schwartz C.M. Steger L. Raeburn, et al. 2001 A phase II study of irinotecan in patients with advanced hepatocellular carcinoma Cancer 91 101 105 10.1002/1097-0142(20010101)91: 1<101::AID-CNCR13>3.0.CO;2-K 11148565 (Pubitemid 32052619)
12. V. Boige J. Taïeb M. Hebbar D. Malka T. Debaere L. Hannoun, et al. 2006 Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level Eur J Cancer 42 456 459 10.1016/j.ejca.2005.09.034 1:CAS:528:DC%2BD28XhsFOjsLk%3D 16427779 (Pubitemid 43227922)
13. P. Canal C. Gay A. Dezeuze J.Y. Douillard R. Bugat R. Brunet, et al. 1996 Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer J Clin Oncol 14 2688 2695 1:CAS:528:DyaK28XmsFCgtrk%3D 8874328
14. J.M.G.H. van Riel C.J. van Groeningen M.A. Kedde H. Gall J.M.A. Leisink G. Gruia, et al. 2002 Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study Clin Cancer Res 8 405 412 11839656
15. M. Hebbar O. Ernst S. Cattan S. Dominguez C. Oprea P. Mathurin, et al. 2006 Phase II trial of docetaxel therapy in patients with advanced hepatocellular carcinoma Oncology 70 154 158 10.1159/000093007 1:CAS:528:DC%2BD28XkslWnsrw%3D 16645329 (Pubitemid 43760342)
16. Y. Chao W.K. Chan M.J. Birkhofer O.Y. Hu S.S. Wang Y.S. Huang, et al. 1998 Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients Br J Cancer 78 34 39 1:CAS:528: DyaK1cXksVynt7o%3D 9662247
17. D. Strumberg J. Erhard A. Harstrick U. Klaassen C. Müller W. Eberhardt, et al. 1998 Phase I study of a weekly 1 h infusion of paclitaxel in patients with unresectable hepatocellular carcinoma Eur J Cancer 34 1290 1292 10.1016/S0959-8049(98)00054-9 1:CAS:528:DyaK1cXltlCgsrc%3D 9849493 (Pubitemid 28342123)
18. Y. Nagata M. Hiraoka Y. Nishimura S. Masunaga M. Mitumori Y. Okuno, et al. 1997 Clinical results of radiofrequency hyperthermia for malignant liver tumors Int J Radiat Oncol Biol Phys 38 359 365 1:STN:280:DyaK2szmvFyrsQ%3D%3D 9226324
19. F. Mohamed P. Marchettini O.A. Stuart M. Urano P.H. Sugarbaker 2003 Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia Ann Surg Oncol 10 463 468 10.1245/ASO.2003.08.006 12734097 (Pubitemid 40486946)
20. Y. Matsuzaki T. Osuga Y. Saito Y. Chuganji N. Tanaka J. Shoda, et al. 1994 A new, effective, and safe therapeutic option using proton irradiation for hepatocellular carcinoma Gastroenterology 106 1032 1041 1:STN:280: DyaK2c7pt12gtA%3D%3D 7511552
21. M. Kawashima J. Furuse T. Nishio M. Konishi H. Ishii T. Kinoshita, et al. 2005 Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma J Clin Oncol 23 1839 1846 10.1200/JCO.2005.00.620 15774777 (Pubitemid 46211361)
22. T. Chiba K. Tokuuye Y. Matsuzaki S. Sugahara Y. Chuganji K. Kagei, et al. 2005 Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients Clin Cancer Res 11 3799 3805 10.1158/1078-0432.CCR-04-1350 15897579 (Pubitemid 40685599)